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Abstract
Background: Vitamin D deﬁciency is frequent and has been associated with fatigue in uncontrolled trials.
Methods:This is the ﬁrst double-blind placebo-controlled clinical trial to investigate the efﬁcacy of per os vitamin D3 (cholecalciferol)
in treating fatigue among otherwise healthy persons with low serum 25-hydroxyvitamin D (25(OH)D) levels. We enrolled 120
individuals (mean age 29±6 years, 53% women) presenting with fatigue and vitamin D deﬁciency (serum 25(OH)D<20mg/L).
Participants were randomized to a single oral dose of 100,000 units of vitamin D or placebo. The primary endpoint was intra-individual
change in the fatigue assessment scale (FAS) at 4 weeks after treatment.
Result:Themean age of the participants was 29±6 years, 53%were women. Mean FAS decreased signiﬁcantly more in the vitamin
D group (3.3±5.3; 95% conﬁdence interval [CI] for change 14.1 to 4.1) compared with placebo (0.8±5.3; 95% CI for change
9.0 to 8.7); (P=0.01). Amelioration of fatigue was reported more frequently in vitamin D than in placebo group (42 [72%] vs. 31
[50%]; P=0.01; odds ratio [OR] 2.63, 95% CI for OR 1.23–5.62). Among all participants, improvement in fatigue score correlated
with the rise in 25(OH)D level (R=0.22, P=0.02).
Conclusion: Vitamin D treatment signiﬁcantly improved fatigue in otherwise healthy persons with vitamin D deﬁciency.
This study was registered at the www.ClinicalTrials.gov Protocol ID NCT02022475.
Abbreviations: 25(OH)D = 25-hydroxyvitamin D, BDI = beck depression inventory, BMI = body mass index, BQF = basic
questionnaire for fatigue, CFS = chronic fatigue syndrome, FAS = fatigue assessment scale, FCA = fatigue course assessment, IQR
= interquartile range, ISI= insomnia severity index, IU= international unit, M.I.N.I=mini international neuropsychiatric interview, MD=
medical doctor, OR = odds ratio, PTH = parathyroid hormone, RCT = randomized clinical trial, TSH = thyroid stimulating hormone.
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1. Introduction
Fatigue is a frequent complaint in primary care in developed and
developing countries.[1] It can lead to impaired quality of life and
loss of productive work time.[2] Physicians are likely to prescribe
vitamins—especially vitamin D, iron, and nutritional supple-
ments to treat the symptom presumptively. In consequence, such
preparations account for a large number of drugs dispensed.
However, there is little scientiﬁc evidence to support this
procedure and practitioners may experience uncertainty due to
lack of available scientiﬁc data.
VitaminD deﬁciency is frequent[3] and has been associated with
fatigue and other unspeciﬁc symptoms including headache,[4]
musculoskeletal pain and weakness,[5] depression,[6] and impaired
cognitive performance.[4] One randomized controlled trial tested
the effect of high-dose vitamin D3 on symptoms in chronic fatigue
syndrome (CFS),where no improvement of fatiguewas found.[7] In
another randomized controlled trial, muscle pains improved in a
population of primary care patients with vitamin D deﬁciency.[8]
Several uncontrolled studies suggested that fatigue may improve
after correction of low vitamin D levels in individuals with stable
chronic diseases,[9] breast cancer,[10] and myasthenia gravis.[11]
However, the results of these studies need to be conﬁrmed by a
double-blind randomized clinical trial (RCT) because strong
placebo effect can inﬂuence investigation of any therapeutic
approach to reduce fatigue.[12]
In this study, we aimed to test if a single vitamin D dose
improves fatigue after 30 days among vitamin D deﬁcient
individuals who report fatigue but are otherwise healthy.
2. Methods
2.1. Study design
This investigator-initiated double-blinded RCTwas conducted in
accordance with the Declaration of Helsinki and the Guidelines
on Good Clinical Practice. The protocol and its amendment were
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approved by the local ethics committee prior to data collection.
All participants gave written informed consent and none received
ﬁnancial compensation. The study was monitored by the
independent Clinical Trial Centre at the University Hospital
Zurich andwas registered at www.ClinicalTrials.gov Protocol ID
NCT02022475.
2.2. Participants
Study participants with fatigue were enrolled at the Medical
Outpatients Division University Hospital Zurich. Healthy
individuals who suffer from fatigue were recruited by posting
announcements on in-house info boards and on the intranet of
the University of Zurich and the University Hospital Zurich.
Healthy subjects of 20 to 50 years with a body mass index (BMI)
of 18 to 25kg/m2 were further evaluated for inclusion.
Exclusion criteria were intake of vitamin D preparations
during 8 weeks prior to study enrollment, pregnancy or lactation,
hypersensitivity to vitamin D, any known cardiovascular,
pulmonary, renal, or hepatic disease, anemia, hyper- and
hypocalcemia (corrected serum calcium levels >2.54mmol/L
or <2.09mmol/L, respectively, the normal range given by the
local laboratory), presence of muscle or bone disease, severe
infection, inﬂammation, malignancy, known mental disorders,
sleep disorders, chronic intake of concurrent medication, except
oral contraceptives, known chronic kidney disease with glomer-
ular ﬁltration rate (CKD-EPI-estimated) <60mL/min/1.73m2,
medication affecting physical or mental performance, participa-
tion in any other therapeutic trial within the previous month,
inability to follow the procedures of the study, for example, due
to language problems, psychological disorders, dementia etc.,
enrollment of the investigator, his/her family members, employ-
ees, and other dependent persons (Supplemental Table, http://
links.lww.com/MD/B463).
2.3. Randomization and masking
Participants were randomly allocated in a 1:1 ratio to receive an
oral dose of 100,000 IU vitamin D (cholecalciferol) or placebo.
The randomization schedule was generated by the hospital
pharmacy prior to start of the recruitment using the software
DatInf GmbH Wilhelmstr (Tübingen, Germany). Blocks of 10
participants, 5 randomly assigned for 100,000 IU vitamin D
(cholecalciferol) and 5 for placebo, were generated. The
randomization list remained preserved by the hospital pharmacy
and was not accessible to the investigators until the end of the
follow-up of the last patient.
The vitamin D study medication and the placebo were
manufactured to have identical appearance, taste and smell.
Two capsules, each containing 50,000 IU vitamin D or placebo
(mannitol), were packed in small sealed plastic cans, tagged with
the corresponding randomization number. These plastic cans
were opened shortly before intake and taken by the participant
under supervision by the study MD.
Participants were instructed not to take vitamin D preparations
or other vitamins and supplements during the entire study period.
2.4. Outcomes
The primary endpoint was intra individual change in the fatigue
assessment scale (FAS) from baseline to 4 weeks (https://
clinicaltrials.gov/ct2/show/NCT02022475).
FAS is a self-reported 10-item paper-and-pencil scale evaluat-
ing symptoms of chronic fatigue with lower scores indicating less
fatigue. A negative change from baseline indicates improvement.
Each of the 10 items has 5 response options (never, sometimes,
regularly, often or always). This score was developed and
validated and showed good psychometric qualities in a
community setting of working population, the mean FAS was
around 19±6 points (range 10–50 points) in such population in
previous studies.[13] Although not validated in German, the FAS
is a comprehensive and easy understandable questionnaire for a
lay person with any education level.
The FAS score includes 2 subscales: physical fatigue andmental
fatigue, with 5 items in each subscale. According to the original
publication, the internal consistency of the FAS test was high at
0.90.[13]
As a secondary endpoint, we investigated the efﬁcacy of
vitamin D administration on fatigue using a short self-developed
fatigue test (fatigue course assessment; FCA). The FCA is a 5-item
self-report paper-and-pencil scale where patients categorize their
current level of fatigue as compared with its level at baseline:
completely resolved = 2, improved = 1, unchanged = 0, worse =
1, much worse =2. By this so far not validated questionnaire,
we aimed to establish a short inventory for future own fatigue
projects.
A further secondary endpoint was the safety of oral
administration of vitamin D based on clinical (physical
examination, adverse events) and laboratory (serum parathyroid
hormone [PTH], calcium, and phosphate levels) ﬁndings.
2.5. Procedures
The schedule of study visits is shown in Supplemental Figure,
http://links.lww.com/MD/B463.
Enrollment criteria fatigue. A validated 4-item basic question-
naire for fatigue (BQF)[14] was applied to conﬁrm fatigue
symptoms at baseline. Accordingly, subjects were considered as
eligible for inclusion if 2 or more points were reached. To exclude
other fatigue-associated disorders such as depression, major
psychiatric and sleep disorders, beck depression inventory
(BDI),[15] mini international neuropsychiatric interview (M.I.N.
I.),[16] and insomnia severity index (ISI)[17] were administered
thereafter. Furthermore, blood was analyzed to exclude anemia,
iron deﬁciency, hyponatremia, kidney, liver and muscle disease,
thyroid disorder, and inﬂammation. A pregnancy test was
performed in all women patients.
2.5.1. Enrollment criteria vitamin D deﬁciency. To qualify for
our enrollment criteria of vitamin D deﬁciency at baseline, we
required a 25(OH)D level below 20mg/L, this threshold has been
used according to the latest report on dietary requirements for
calcium and vitamin D from the Institute of Medicine.[18,19]
25(OH) vitamin D was analyzed at the time of the screening
assessment in the Institute of Clinical Chemistry, University
Hospital of Zurich, using an automated immunoassay (Cobas
8000 Analyser; Roche Diagnostics, Rotkreuz, Switzerland).
Additional laboratory measures included: intact PTH, calcium,
phosphate, hemoglobin, ferritin, thyroid-stimulating hormone,
C-reactive protein, alanine aminotransferase, alkaline phospha-
tase, creatinine, creatine kinase.
2.5.2. Clinical visits.The ﬁrst clinical visit was the screening visit
where exclusion and inclusion criteria were assessed. The body
weight and height were measured; BMI was calculated as the
weight in kilograms divided by the square of the height in meters.
Eligible individuals who also signed written informed consent
were invited to the baseline visit.
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The baseline visit was scheduled to be 2 weeks after the
screening visit. At this visit, the FAS questionnaire[13] was
completed by the participant. Blood pressure was measured after
5minutes’ rest in a sitting position. Blood was taken to determine
25(OH)D, intact PTH, serum phosphate, and serum calcium.
Following this, a single oral dose of 100,000 units of vitamin D or
placebo was administered, supervised by the study MD.
The follow-up visit took place 4 weeks (+ maximum 7 days)
after the baseline visit and ingestion of the study medication. The
time interval between the baseline and follow-up visit was deﬁned
based on reported pharmacokinetics of a high-dosage vitamin D
administration,[20–22] in the study by Romagnoli et al,[21] the
highest 25(OH)D- and the lowest PTH-level were achieved at day
30 after a per oral bolus high dose vitamin D application. Because
we hypothesized that fatigue can be improved by vitamin D
treatment, we assumed that the best improvement effect should
be achieved at the maximum of vitamin D levels after treatment.
Again, the FAS questionnaire was ﬁlled in by the participant.
Additionally, FCA was applied. Thereafter, the same laboratory
values were measured at the follow-up visit as at the baseline visit.
2.6. Adverse events
Adverse events were reported by the patients or assessed by the
study physicians at the 4 weeks’ follow-up visit.
2.7. Statistical analysis
Categorical variables were expressed as proportions, continuous
variables as means with standard deviations and medians with
interquartile ranges (IQR). Comparisons between the study
groups were performed using the t test, Mann–WhitneyU test, or
the Chi-square test as appropriate. Correlations were determined
according to the method of Pearson. Intention-to-treat analysis
included all patients randomized, treated and completing the
follow-up visit. All statistical tests were 2-sided, and P values
<0.05 were considered signiﬁcant. The whole data set was
complete.
A power calculation indicated a minimum of 25 patients per
treatment group to detect an effect size of 20% (a=0.05; b=0.2).
The power analysis was performed on the basis of previously
published clinical fatigue studies in sarcoidosis due to lack of
randomized studies using FAS in vitamin D treatment.[23] We
enrolled more patients in our study based on the assumption that
the FAS treatment effect may be lower in otherwise healthy
individuals.
3. Results
Between February 2014 and April 2015, we screened 286
participants and enrolled 128 in the study. The reasons for
exclusion of 158 patients were: 25-OH vitamin D levels>20mg/L
(n=103), ISI or BDI score too high (n=14), ferritin below the
normal range (n=12), thyroid stimulating hormone (TSH) above
the normal range (n=9), BMI too high (n=9), refusal to
participate (n=3), concurrent medications (n=2), hemoglobin
below the normal range (n=2), no blood was taken (n=1), BQF
score too low (n=1), pregnancy (n=1), creatine kinase above
normal range (n=1). Six participants withdrew informed content.
A total of 122 participants underwent the baseline visit and
took the 1-time study medication (59 received the vitamin D and
63 the placebo study medication). One participant was excluded
from the analysis (blinded to the treatment group) according to
the protocol due to starting venlafaxine after the baseline visit, 1
participant was lost to follow-up. In total, 120 participants (58 in
the vitamin D and 62 in the placebo group) were included into
per-protocol analysis (study ﬂow diagram); the analysis was by
the original assigned groups.
At baseline, the study groups were well balancedwith regard to
age, sex, BMI, blood pressure, and laboratory parameters. There
was no difference concerning fatigue (24±5 vs 25±5 points on
FAS; P=0.11) and 25-OH vitamin D levels (13 [10–18] vs 14
[10–18] mg/L; P=0.50) between the vitamin D and placebo
group (Table 1).
Among the patients who underwent the post-baseline evalua-
tion, 77 (64%) were enrolled in winter, 38 (32%) in spring, 1
(1%) in summer, and 4 (3%) in fall. Among them, 110 (92%)
were Caucasian, 1 (1%) Black, 6 (5%) Asian, and 3 (3%) Indian.
The allocation to the treatment groups did not differ by season
(P=0.60) or ethnicity (P=0.57).
3.1. Primary endpoint
Over 4 weeks, the mean FAS decreased signiﬁcantly more in the
vitamin D group (3.3±5.3; 95% conﬁdence interval [CI] for
change 14.1 to 4.1) compared with placebo (0.8±5.3; 95%
CI for change 9.0 to 8.7); (P=0.01) (Fig. 1, Table 2). FAS
improved signiﬁcantly only in the vitamin D (P<0.001) but not
in the placebo (P=0.24) group (Fig. 2). Amelioration of fatigue
was reported more frequently in vitamin D than in placebo group
(42 [72%] vs 31 [50%]; P=0.01; odds ratio [OR] 2.63, 95% CI
for OR 1.23–5.62).
A greater improvement of FAS was associated with a greater
increase in the 25(OH)D level (R=0.22; P=0.02).
Table 1
Baseline characteristics.
Vitamin D N=58 Placebo N=62
Age, y 29±7 28±6
Gender
Females, n (%) 31 (53) 33 (52)
Body mass index
∗
22 [21–24] 22 [21–24]
Arterial blood pressure, mmHg
Systolic 124±11 125±11
Diastolic 78±8 76±8
Blood analysis
25-OH-vitamin D, mg/L 13 [10–18] 14 [10–17]
Parathyroid hormone, ng/L 45±16 46±17
Calcium, mmol/L† 2.22±0.07 2.22±0.07
Phosphate, mmol/L 1.00±0.19 1.02±0.15
Hemoglobin, g/L 145 [137–153] 143 [134–155]
Ferritin, ng/mL 104±75 92±75
Thyroid-stimulating hormone, mU/L 1.64 [1.32–2.13] 1.52 [1.09–2.14]
C-reactive protein, mg/L 0.94±1.2 1.22±1.7
Alanine aminotransferase, U/L 17 [13–24] 19 [14–26]
Alkaline phosphatase, U/L 52 [44–64] 57 [48–67]
Creatinine, mmol/L 71 [61–80] 75 [64–83]
Creatine kinase, U/L 111±49 128±85
There were no signiﬁcant differences (at P<0.05) between the 2 groups with respect to any of the
baseline characteristics.
Results are presented as means±SD or, medians [IQR] or number of patients (%). P values were
calculated using t test, Mann–Whitney U test or Chi-square test.
To convert the values for calcium to milligrams per deciliter, multiply by 4000. To convert the values for
phosphate to milligrams per deciliter, multiply by 3.0969. To convert the values for creatinine to
milligrams per deciliter, divide by 88.
∗
The body-mass index is the weight in kilograms divided by the square of the height in meters.
† Corrected for serum albumin concentration.
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If calculating including the participant who started taking
venlafaxine after the baseline visit (intention-to-treat analysis),
the mean FAS still decreased signiﬁcantly more in the vitamin D
group (3.2±5.3; 95% CI for change 14.0 to 4.0) compared
with placebo (0.8±5.3; 95% CI for change 9.0 to 8.7)
(P=0.01).
3.2. Secondary endpoints
Improvement in fatigue at the 4 weeks’ follow-up visit, as
assessed by the self-developed FCA, was reported by 28 (48%) of
vitamin D treated and 23 (37%) of placebo-treated patients (P=
0.22) (OR 1.58; 95% CI for OR 0.76–3.28).
A signiﬁcant increase in 25-OH vitamin D was observed in
vitamin D but not in placebo-treated participants (14.0±5.4 vs
0.3±3.2mg/L; P<0.001). A signiﬁcant decrease in PTH
levels in vitamin D-treated and an increase in placebo-treated
participants was observed (2.6±13 vs 3.9±18ng/L; P=0.03).
Calcium and phosphate levels remained unchanged in both
groups (Table 2).
The number of participants reporting adverse events and the
number of adverse events per patient was similar in both groups
(Table 3). No serious events occurred. The most often reported
adverse event was infection, the majority viral upper respiratory
likely due to the inﬂuenza outbreaks in spring and winter 2014
and 2015, when the most patients were recruited.
4. Discussion
This is the ﬁrst double-blind RCT that tested a 1-time vitamin D
treatment among otherwise healthy vitamin D deﬁcient individ-
uals with fatigue, were strict criteria were used to exclude
common medical conditions potentially causing fatigue. Our
results showed that 100,000 IE single dose vitamin D treatment
lead to a signiﬁcant improvement in fatigue in the vitamin D
group compared with the placebo group. Moreover, improve-
ment in fatigue modestly but signiﬁcantly correlated with the
change in 25(OH)D levels among all participants. The vitamin D
treatment was shown to be well-tolerated.
In this study, we enrolled fatigued persons not suffering from
other physical or mental illnesses but with 25-hydroxyvitamin D
levels below 20mg/L.[18,19]
The strength of our study is the placebo-controlled design in a
population where main causes of fatigue were excluded using
validated tools. Vitamin D treatment led to a signiﬁcant reduction
in parathyroid hormone secretion, along with an increase in 25
Figure 2. Fatigue at baseline and after 4 weeks in the vitamin D-treated and
placebo-treated group (dotted lines correspond to means).
Figure 1. Change of fatigue assessment scale depending on the adminis-
tration of vitamin D or placebo (dotted lines correspond to means).
Table 2
Change in fatigue assessment scale and blood parameters 4
weeks after vitamin D treatment.
Vitamin D group Placebo group P
Change in fatigue
Fatigue (FAS) 3.3±5.3 0.8±5.3 0.01
Fatigue improved, n (%) 42 (72) 31 (50) 0.01
Fatigue assessment scale
At baseline 24.9±5.4 23.3±5.4 0.11
At 4 weeks 21.6±5.8 22.5±5.9 0.41
Change in blood parameters
25-OH vitamin D, mg/L 14.0±5.4 0.3±3.2 <0.001
Parathyroid hormone, ng/L 2.6±13 3.9±18 0.03
Calcium, mmol/L
∗
0.01 [0.03–0.7] 0.01 [0.05–0.7] 0.68
Phosphate, mmol/L 0.02±0.18 0.02±0.24 0.99
Results are presented as means±SD or as medians [IQR]. P values were calculated using t test,
Mann–Whitney U test or Chi-square test.
FAS= fatigue assessment scale, FCA= fatigue course assessment.
∗
Corrected for serum albumin concentration.
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(OH)D, indicating a treatment effect and conﬁrming the
biological 25(OH)D deﬁciency at baseline.
It should be noted that the study population consisted of
healthy individuals responding to an advertisement. Therefore, it
remains to be further elucidated if the treatment effect would be
less or as great or greater in a help seeking population in primary
care settings. Importantly, the generalizability of the ﬁndings is
limited to an otherwise healthy population, in an elderly more ill
population, a high-dose vitamin D therapy showed an increase in
fall incidence.[24] Also, our study is limited by its short-term
follow-up and should serve as a pilot study for future vitamin D
treatment on fatigue trials. Moreover, the study results are not
generalizable to milder vitamin D insufﬁciency. A further
potential disadvantage is that we did not enroll all patients at
the same time of year in order to equalize sunlight exposure,
which may inﬂuence fatigue independently of sun-induced
vitamin D synthesis in the skin. However, allocation to the
treatment groups was similar between seasons, as shown in the
results section. A further possible limitation of our study is the
lack of fatigue-associated further endpoints such as muscle pains
and strength, quality of life and cognition. On the other hand, by
using 1 primary end-point, we potentially avoid a multi-testing
issue. Finally, this study does not answer the question to what
extent treatment with vitamin D also reduces other harms
associated with fatigue, such as occupational impairment or costs
of care. Last but not least, future prospective randomized studies
should also address the question if the parameters of cardiovas-
cular health could be improved by vitamin D treatment. Study by
Witham et al[7] previously showed no improvement of CFS
following a high-dose intermittent oral vitamin D therapy. There
are possible explanations why our study results are different.
First, Witham et al[7] used the Fukuda et al[25] and Carruthers
et al[26] CFS criteria for the study inclusion. In contrast, our
population had no underlying illnesses and was younger. Patients
with CFS may suffer from fatigue of a multidimensional origin,
arising from an underlying medical condition, comedication,
inﬂammation, and other pathologies. Importantly, our study
results are not generalizable to CFS. Second, we included
participants with lower vitamin D levels in whom vitamin D
replacement may have led to a more pronounced effect.
Previous prospective non-randomized studies suggested that
normalization of vitamin D status signiﬁcantly improved severity
of fatigue in patients with various medical conditions.[9–11]
However, self-reported improvements in fatigue are highly
susceptible to placebo effects,[12] which are also evident in our
own placebo group (Table 2, Fig. 2). We, therefore, chose to
conduct a double-blind placebo-controlled trial.
While the effects of vitamin D on fracture and fall prevention
among vitamin D deﬁcient seniors are well investigated,[24] other
non-skeletal effects of vitamin D are increasingly attracting
research interest,[27] but lack evidence from double-blind
RCTs.[18] The mechanism by which vitamin D treatment may
improve fatigue is unknown. However, the vitamin D receptor
has been shown to be present in many areas of the brain.[28]
Central fatigue has been proposed to arise from a dopamine
imbalance within the central nervous system and the vitamin D
receptor has been demonstrated in dopaminergic neurons of
human and rat midbrain; these neurons have been found to be
regulated by the active form of vitamin D.[29] Moreover, vitamin
D has been shown to act as key regulator of brain serotonin
synthesis.[30] Additional clinical and experimental evidence
suggests that a defect in serotonergic function might also be
associated with fatigue.[31] These changes may potentially lead to
an improvement of physical function and of depressive
symptoms. Furthermore, cholecalciferol therapy increases muscle
mitochondrial oxidative phosphorylation in vitamin D deﬁcient
individuals, potentially leading to a modulation of fatigue.[32] In
agreement with the latter observation, vitamin D was found to
inﬂuence oxidative phosphorylation in rat liver mitochondria.[33]
In conclusion, our study shows that a single dose of oral
100,000 IE vitamin D3 is an effective, well-tolerated, and
economical treatment strategy for healthy adults who report
fatigue.
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